Statistical programmers at all levels can make a significant impact on streamlining delivery, improving efficiency, and importantly ensuring quality. At a recent PhUSE Single Day event , Cytel's Sunil Gupta gave a very well received presentation on how best to achieve high quality deliverables while maintaining efficiency, noting that 3 key components should be observed:
Apr 5, 2017 11:39:42 AM
Mar 29, 2017 8:29:00 AM
With an increasing interest in platform designs and other innovative designs that involve multiple comparisons over multiple stages, the importance of Multi-Arm Multi-Stage ( MAMS) designs is set to rise.
Mar 24, 2017 9:27:00 AM
Robust go/no-go (GNG) decision-making is essential for effectively managing risk across a clinical portfolio. In early phase development, it is particularly important to have the correct tools in place to terminate ineffective compounds quickly, while accelerating promising ones through the process.
Mar 20, 2017 9:54:00 AM
In the randomized clinical trial (RCT), the process of deciding the randomization method and implementing is critically important. Unfortunately, it is not unheard of for problems to arise. In an article (Downs et al 2010 1), it is noted that as well as initial errors of trial design, problems can arise from errors with programming of the randomization or even human error during the course of...
Mar 15, 2017 8:51:00 AM
A precise and thorough approach to planning is key for success in data management.
The Data Management Plan (DMP) is a critical document in any data management project. It outlines all of the data management work to be done, the timelines and milestones to be achieved, as well as the outputs to be produced. The DMP lets all of the stakeholders know what to expect, how to expect it and when...
Mar 10, 2017 7:19:33 AM
At the recent Biosimilars Summit in Philadelphia, Cytel's Pantelis Vlachos presented on statistical challenges and flexible approaches in biosimilar development. In this blog we summarize some of the challenges and share the slides from talk.
Mar 2, 2017 8:45:00 AM
We continue our case study series with this example of a Phase 3 design that uses Bayesian decision making combined with frequentist final analysis.
Clinical Development Background
Our biopharmaceutical client’s lead drug candidate is a late clinical-stage cancer immunotherapy for treatment of a rare oncology indication. Clinical development of therapies in this indication faces inherent...
Feb 27, 2017 7:39:00 AM
It’s been hard to miss the prevalence of estimand-related discussions in the last year. This is a topic which is very much at the forefront of statistics discussions right now. We are lucky enough to welcome Mouna Akacha to the blog to give us the lowdown on estimands and the problems and opportunities they represent for the global biopharma industry.
Mouna is a Consultant in the...
Feb 21, 2017 9:39:07 AM
In a previous blog, we provided an overview of basic data structures in R. In this follow up piece, we will provide a snapshot of basic syntax in R for programmers who want to get up to speed in this increasingly important programming language.
Feb 15, 2017 9:33:05 AM
Outsourcing solutions should never be a one size fits all process, and smaller and emerging biopharma companies may have different priorities and processes when working with external vendors to larger pharmaceutical organizations.
Feb 9, 2017 7:34:58 AM
In this blog, Adam Hamm, PhD, Director Biostatistics at Cytel shares some of the most important knowledge he uses in his day to day work as a biostatistician working extensively in oncology research. Adam has broad experience with statistical analysis and methodology over all phases (I-IV) of development, in particular working in the oncology arena.
As a Director of Biostatistics at...
Feb 6, 2017 9:10:00 AM
CDISC is a global, nonprofit charitable organization whose mission is ‘to inform patient care and safety through higher quality medical research’. The organization delivers this mission through the development of data standards designed to streamline clinical research- these standard formats are increasingly expected for use in data submissions by regulatory authorities. Importantly, data...
Jan 30, 2017 9:50:24 AM
Single ascending dose (SAD) and multiple ascending dose (MAD) studies are typically the first in human studies. They seek to gain information on safety and tolerability, general pharmacokinetic (PK) and pharmacodynamic ( PD) characteristics, and of course identify the maximum tolerated dose (MTD).
Conventionally, SAD and MAD studies were conducted separately, but increasingly are combined...
Jan 23, 2017 10:35:00 AM
As a group, Cytel had over 40 successful regulatory interactions last year, many of which supported approvals for innovative trial design approaches. In this blog we look at some of the key success factors for regulatory interactions regarding adaptive designs.
Jan 19, 2017 7:05:00 AM
R is on the rise in biopharma, and as we have previously discussed on the blog, it is now time for SAS programmers to get up to speedwith this popular and powerful programming language. Indeed, one of the advantages of R is its ability to integrate with other languages like C, C++, Python and SAS. Its strong graphical capabilities allow output in PDF, JPG, PNG, and SVG formats and table...
Jan 16, 2017 8:41:00 AM
The Global Cardiovascular Clinical Trialists Forum is a key event bringing together leading experts from across the spectrum of opinion leaders, clinical trialists, investigators, regulators, statisticians and practitioners to address the most pressing questions in cardiovascular clinical development today. At the December conference, eminent biostatisticians Cyrus Mehta and Stuart Pocock...
Jan 5, 2017 8:45:00 AM
Nonlinear Mixed Effects Modeling (NONMEM) is a type of population pharmacokinetics/pharmacodynamics (popPK/PD) analysis used in Clinical Pharmacology research. The population PK approach combined with pharmacodynamics modeling, allows integrated analysis, interpretation, and prediction of the drug’s safety, efficacy, dose-concentration relationship, and dosing strategy.
Dec 23, 2016 8:21:00 AM
As we prepare to say 'so long, farewell' to 2016, we'd like to take the opportunity to thank all our blog readers and subscribers. Read on for a round up of our most read topics from the year....
Dec 21, 2016 9:45:00 AM
December 18th 2016 was a significant date for the pharmaceutical industry and regulatory submissions. For trials which commence after this date, the FDA will no longer accept non-CDISC data submissions for new drug applications ( NDAs) , certain investigational new drug applications, abbreviated new drug applications (ANDAs) and certain biologics license applications (BLAs).
Dec 20, 2016 9:21:00 AM
Data Standards play a crucial role in structuring and promoting long term value of clinical data.
Clinical Data Acquisitions Standards Harmonization or CDASH was developed with participation from all three ICH regions (US, Europe and Japan) with recommended data collection fields for 16 domains-> DEMOG, AE etc. It also includes implementation guidelines, best practice recommendations, and...